Table 3.
Sorafenib+vitamin K (n=29) | Sorafenib alone (n=36) | |
---|---|---|
Complete response n (%) | 0 (0) | 0 (0) |
Partial response n (%) | 10 (34) | 5 (14) |
Stable disease n (%) | 10 (34) | 5 (14) |
Progressive disease n (%) | 9 (31) | 25 (69) |
Not assessable n (%) | 0 (0) | 1 (3) |
aDisease control rate n (%) | 20 (69.0) | 8 (22.9) |
a P<0.001
RECIST: Response Evaluation Criteria in Solid Tumors